Microchip implant could personalize cancer drug selection
NCT ID NCT05553782
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a small implantable device that delivers tiny amounts of different drugs directly into head and neck tumors. The goal is to see which drugs are most effective for each person before they undergo full treatment. The study involves 30 adults with certain head and neck cancers who are scheduled for surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA OF THE SALIVARY GLAND are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?